BB&T Securities’s BioMarin Pharmaceuticals BMRN Stock Holding History

BB&T Securities’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$230K	Buy	3,460 +13	+0.4%	+$1K	﹤0.01%	1445
2019 Q2	$295K	Buy	3,447 +132	+4%	+$11.3K	﹤0.01%	1319
2019 Q1	$294K	Buy	3,315 +170	+5%	+$15.8K	﹤0.01%	1301
2018 Q4	$267K	Buy	3,145 +245	+8%	+$23.3K	﹤0.01%	1231
2018 Q3	$281K	Sell	2,900 -5,803	-67%	-$579K	﹤0.01%	1341
2018 Q2	$819K	Buy	+8,703	New	+$762K	0.01%	881

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BB&T Securities's BMRN Position: Q3 2019 in Review

BB&T Securities increased its BioMarin Pharmaceuticals (BMRN) stake by 0.38% in Q3 2019, buying an estimated $1K and bringing the position to 3,460 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

BB&T Securities first reported a position in BMRN in Q2 2018 and has held it in 6 quarters since. The position peaked at $819K in Q2 2018. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

BB&T Securities held 3,460 shares of BioMarin Pharmaceuticals worth $230K as of Q3 2019.
BB&T Securities bought 13 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1K.
BioMarin Pharmaceuticals made up ﹤0.01% of BB&T Securities's portfolio in Q3 2019, its #1445 holding.
BB&T Securities first reported a position in BioMarin Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
BB&T Securities's BioMarin Pharmaceuticals position peaked at $819K in Q2 2018.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.